PAUL BROWN: Open Payments
NPI 1003862376 · TORRANCE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$552 in 27 payments from 10 companies in 2025. Trend: 2023 $988 · 2024 $684 · 2025 $552
Food & beverage: $552
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $129 |
| PFIZER INC. | 4 | $103 |
| Amgen Inc. | 4 | $84 |
| Novo Nordisk Inc | 3 | $54 |
| Axsome Therapeutics, Inc. | 2 | $54 |
| Lilly USA, LLC | 2 | $42 |
| Phadia US Inc. | 1 | $30 |
| GlaxoSmithKline, LLC. | 1 | $25 |
| Intra-Sana Laboratories | 1 | $17 |
| Exact Sciences Corporation | 1 | $15 |
Products named: AIRSUPRA, PREVNAR 20, OTEZLA, Auvelity, MOUNJARO, FARXIGA, ImmunoCAP, REPATHA.
Industry payments across CA — which companies pay providers there.
